On October 3, 2023 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa’s novel ovarian cancer vaccine technology (Press release, Anixa Biosciences, OCT 3, 2023, View Source [SID1234635590]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent, titled "Ovarian Cancer Vaccines", was invented by the late Dr. Vincent Tuohy of Cleveland Clinic and covers nucleic acid-based delivery of the vaccine. Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.

Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are delighted to receive this patent from the USPTO as it broadens protection of our novel ovarian cancer vaccine technology. We are looking forward to continuing our preclinical work on the vaccine with support from the National Cancer Institute’s PREVENT Program, a peer-reviewed program designed to support development of the best ideas in cancer prevention."

Anixa’s ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.